Improved Fatigue Management in Primary Sjögren's Syndrome: A Retrospective Analysis of the Efficacy of Methotrexate in Chinese Patients
Meiju Zhou,Xiaona Dai,Fang Yuan
DOI: https://doi.org/10.2147/jir.s475605
IF: 4.5
2024-10-22
Journal of Inflammation Research
Abstract:Meiju Zhou, Xiaona Dai, Fang Yuan Department of Rheumatology and Immunology, Zhejiang Hospital, Hangzhou, People's Republic of China Correspondence: Fang Yuan, Department of Rheumatology and Immunology, Zhejiang Hospital, No. 1229 Gudun Road, Hangzhou, 310030, People's Republic of China, Email Objective: To assess the efficacy of methotrexate (MTX) and hydroxychloroquine (HCQ) in improving fatigue symptoms in patients with primary Sjögren's syndrome (pSS). Methods: A single-center retrospective study was conducted on pSS patients experiencing fatigue symptoms. All patients received either MTX, HCQ, or a combination of MTX + HCQ for a period of six months. Clinical efficacy was measured using the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI), EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), fatigue severity scale (FSS), and visual analog scale (VAS) score. These measures were assessed at baseline and at 1, 2, 3, and 6 months. Results: A total of 86 pSS patients with fatigue symptoms were enrolled (27 received MTX, 29 received HCQ, and 30 received MTX + HCQ). Patients receiving MTX and MTX + HCQ showed significant improvements at 6 th month in ESSDAI, ESSPRI, FSS, FACIT-F, and VAS scores (all P < 0.01) compared with baseline. Repeated-measures analysis of variance revealed that patients treated with MTX and MTX + HCQ experienced significant improvements in ESSDAI, FSS, FACIT-F, and VAS scores (all P < 0.01) from baseline to the 6 th month. The HCQ group did not show significant improvement in FSS, FACIT-F, and VAS scores (all P > 0.05), although their ESSDAI and ESSPRI scores did improve significantly (all P < 0.01). Patients in the MTX group showed the most improvement in mean changes of ESSDAI score, FSS score, FACIT-F score, and VAS score from baseline to the 6 th month. And patients received MTX treatment significantly had more fatigue remission numbers (all P < 0.05). Conclusion: In clinical practice, methotrexate is more effective than hydroxychloroquine in improving fatigue symptoms, as measured by patient-reported fatigue scales (FSS, FACIT-F, and VAS scores) in patients with pSS. Keywords: primary Sjögren's syndrome, fatigue, methotrexate, hydroxychloroquine Primary Sjögren's syndrome (pSS) is a multisystemic autoimmune disease, second only to rheumatoid arthritis in frequency. 1 Typical symptoms of pSS include oral and ocular dryness, fatigue, and pain. These symptoms are characterized by hypofunction of the salivary and lacrimal glands, and possible systemic multi-organ manifestations that primarily affect women. 2,3 Current evidence suggests that approximately 75% of pSS patients produce autoantibodies of the Sjögren's Syndrome A (SSA/Ro) and -B (SSB/La) type. 4 The majority of pSS patients experience persistent pain, fatigue, and ocular and/or oral dryness. 5 Fatigue is a complex and disabling symptom affecting between 22 and 30% of the general population, resulting in reduced quality of life. 6 Nearly 70% of patients with pSS report profound, debilitating fatigue as the single symptom with the most significant negative impact on their quality of life. 7 The prevalence of fatigue in pSS patients is reported to range from 67% 8 to 85%. 9 It is now understood that pSS-related fatigue differs from general fatigue in that it is constant, unrelenting, and volatile. Patients with pSS describe fatigue as "an ever-present, fluctuating, and non-relievable lack of vitality beyond one's own control". 10 This symptom is reported as the most challenging to manage. 11 This underscores the importance of identifying effective treatment strategies to improve fatigue in patients with pSS. 12 However, the mechanisms that lead to and regulate fatigue are debated. The etiology of fatigue is very complex and unclear, and may be multifactorial, including biological and psychosocial elements contributing to the perception of fatigue. Fatigue symptoms are frequently observed in immune-mediated inflammatory conditions and consistently follow autoimmune diseases, tumors, and infections. This is part of a constellation of symptoms termed "sickness behavior". 6,13 As reported by S.V. Arnett et al, proinflammatory cytokines may play a critical role as the biological basis of fatigue. 13 Evidence suggests that genetic and molecular mechanisms are activated during inflammation and cellular stress conditions, and signaled via neuro-immune and oxidative / nitrosative stress pathways. 14 Currentl -Abstract Truncated-
immunology